Company

Investors

GlycoVaxyn is a private Swiss biotechnology company developing a broad portfolio of novel bioconjugate vaccines and therapeutics to prevent and treat common, severe bacterial infections using its proprietary glycoprotein technology.

GlycoVaxyn was founded in 2004 as a spin-out company from the Swiss Federal Institute of Technology (ETH) to commercialize the glycoprotein technology developed by its scientific founder. GlycoVaxyn is based in Schlieren, near Zurich, Switzerland, and has raised over CHF 12.5 million (ca. US$ 10.4 million) in equity funding from its blue chip venture capital investors, Sofinnova Partners (Paris) and Index Ventures (Jersey, Geneva, London). In March 2009 the company announced the successful closing of a CHF 25 million (approx. US$ 22 million, € 17 million) series B financing. The round was led by Edmond de Rothschild Investment Partners.